Year: 2016
Language: Polish
Also Available In: English, Spanish, French, Arabic, Russian, Simplified Chinese
This is not an official WFH translation. This resource has been translated with permission by a WFH National Member Organization (NMO), and is shared here with their kind permission. Translating organizations are encouraged to have translations reviewed by local experts, the WFH is not responsible for the translation or for any errors or changes to content from the original English edition. Patient organizations interested in translating a WFH resource must first obtain permission from the WFH, available here.
Desmopressin (DDAVP) may be the treatment of choice for patients with mild or moderate hemophilia A and type 1 von Willebrand disease (VWD). This Fact Sheet presents essential information about this synthetic medicine which costs much less than plasma products or recombinant clotting factor concentrates, carries no risk of transmission of viral infections, and is on the World Health Organization’s (WHO) Model List of Essential Medicines (EML).
This video gives a quick introduction to ultra-long half-life (UHL) clotting factor replacement therapy. Learn more about different treatment options
The WFH Shared Decision Making (SDM) Workbook is for people with hemophilia A or B and their healthcare team. It
The World Federation of Hemophilia (WFH) Shared decision-making (SDM) tool helps clinicians and people with hemophilia work together to make
The WFH Shared Decision Making (SDM) Tool is an interactive decision-support system designed to facilitate discussions regarding treatment options between
This fact sheet contains commonly asked questions and more information on gene therapy for hemophilia B. Learn more about different
This video gives a quick introduction to hemostatic rebalancing therapy. Learn more about different treatment options for hemophilia with the
